Roche Holding AG (ROG.EB) said that a phase 3 IMpower150 study showed an improvement in the treatment of advanced lung cancer with the use of Tecentriq.

ADC Biotechnology (ADC Bio) announces that it is developing a revolutionary, ‘downstream bioconjugation’ method that will present a new paradigm in Antibody Drug Conjugate (ADC) development and manufacturing.

Inovio Pharmaceuticals, Inc. and the Parker Institute for Cancer Immunotherapy have entered into a clinical collaboration agreement that provides for Inovio and the Parker Institute to undertake clinical evaluation of novel combination regimens within the field of immuno-oncology.

The Johnson & Johnson Human Performance Institute today announced it is expanding its footprint in the Lake Nona community in Orlando, Florida with the construction of its new global headquarters.

Adverum Biotechnologies, Inc. (Nasdaq:ADVM), a clinical-stage gene therapy company targeting unmet medical needs in serious rare and ocular diseases, announced an extension of its collaboration agreement with Editas Medicine, Inc. (Nasdaq:EDIT).

STORM Therapeutics, the leading drug discovery company focused on small molecule therapies modulating RNA modifying enzymes, announced that it has raised an additional GBP4 million of funding from Taiho Ventures, LLC the strategic corporate venture capital arm of Taiho Pharmaceutical Co., Ltd.